Novel agents for resistant Gram-positive infections--a review (Q34666658)

3 August 2017

1 reference

title

Novel agents for resistant Gram-positive infections--a review (English)

1 reference

3 August 2017

main subject

gram-positive bacteria

0 references

1

Jacob Strahilevitz

1 reference

3 August 2017

Ethan Rubinstein

2

1 reference

3 August 2017

publication date

1 March 2002

1 reference

International Journal of Infectious Diseases

3 August 2017

published in

1 reference

3 August 2017

volume

6 Suppl 1

1 reference

3 August 2017

page(s)

S38-46

1 reference

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates.

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Linezolid resistance in a clinical isolate of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surve

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Suboptimal effect of daptomycin in the treatment of bacteremias

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Daptomycin disrupts membrane potential in growing Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

LY146032: activity and resistance development in vitro.

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Once-daily dosing in dogs optimizes daptomycin safety

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Development of daptomycin for gram-positive infections

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

A novel glycylcycline, 9-(N,N-dimethylglycylamido)-6-demethyl-6-deoxytetracycline, is neither transported nor recognized by the transposon Tn10-encoded metal-tetracycline/H antiporter

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aure

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Antimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

Novelties in the field of anti-infective compounds in 1999.

1 reference

https://api.crossref.org/works/10.1016/S1201-9712(02)90153-0

7 January 2021

10.1016/S1201-9712(02)90153-0

Identifiers

DOI

1 reference

3 August 2017

1 reference